(lp0
S"Gilead Sciences: Wait, Its Pipeline Isn't Completely Barren? Barron's  - 13 hours ago Shares of Gilead Sciences  have been under pressure ever since investors realized its hepatitis-C sales weren't going to be able to keep growing.3 Numbers That Make Gilead Sciences, Inc. Look Cheaper Than It Really Is - Motley FoolThe Massmutual Trust Co. FSB ADV Takes Position in Gilead Sciences, Inc.  - Petro Global News 24"
p1
aS'Gilead Sciences, Inc.  Ex-Dividend Date Scheduled for March 14, 2017 Nasdaq - Mar 13, 2017 Gilead Sciences, Inc.  will begin trading ex-dividend on March 14, 2017. A cash dividend payment of $0.52 per share is scheduled to be paid on March 30, 2017.3 M&amp;A Scenarios For Gilead Sciences - Seeking AlphaIs It Time to Sell Gilead Sciences ? - Smarter Analyst'
p2
aS"Gilead defended at Jefferies Seeking Alpha - 12 hours ago &quot;ACC inhibitor GS-0976 - one of Gilead's  least-talked-about assets in NASH, in our opinion - appears to have demonstrated significant positive effects in the as-yet-unreported ph."
p3
aS"Here's Why the Best Is Yet to Come for Gilead Sciences, Inc. Motley Fool - Mar 7, 2017 Several of its most promising pipeline prospects are still years away from commercialization. All of these statements are true for Gilead Sciences . But is the big biotech destined for perpetual malaise? Not hardly. Here's why the best is ...Barclays Analyst Pens Open Letter To Gilead Board And Management - BenzingaGilead Sciences: Just Any Deal Won't Do - Barron's "
p4
aS"Better Buy: Biogen Inc. vs. Gilead Sciences Inc. Motley Fool - Feb 27, 2017 Biogen  and Gilead Sciences  don't compete against each other -- at least not yet. Both biotechs are interested in the oncology and autoimmune disease therapeutic areas, so there's always a chance they could become rivals.Gilead Sciences Is Heading To $57 - Seeking AlphaGilead Sciences to Present at the Barclays Global Healthcare Conference on ... - Yahoo Finance"
p5
aS'Insider Cuts Losses on Valeant Pharmaceuticals Intl Inc , Gilead Sciences ... Smarter Analyst - Mar 14, 2017 Canaccord and Goldman Sachs are cautiously reigning in price targets on Valeant Pharmaceuticals Intl Inc  and Gilead Sciences, Inc. . Whereas one analyst spots a red flag ahead as investors scatter in the fray of Pershing&nbsp;...'
p6
aS"Should The US Government Buy A Drug Company To Save Money? NPR - Mar 17, 2017 Since 2013, when Gilead Sciences Inc. released Sovaldi, the first medication that can reliably cure hepatitis C, health insurers and state Medicaid programs have been coming up with ways to limit access to it and a sister drug, Harvoni, because they're ..."
p7
aS"Gilead Sciences Heading South? Seeking Alpha - Mar 1, 2017 Gilead Sciences is still a great company with a war chest of capital waiting to be deployed, unlocking future growth.Gilead Sciences: M&amp;A to the Rescue? - Barron's Checking the Overall Picture for Gilead Sciences Inc.  - StockNewsJournal"
p8
aS"What Analysts are Predicting For Exxon Mobil Corporation , Gilead ... The USA Commerce - 14 hours ago Shares of Exxon Mobil Corporation  dropped -0.09% to $82.00. During the trading on 03/17/2017, Company's stock ranged from $81.82 to $82.26."
p9
aS"Gilead: Despite The Incyte Rumors There Is Still Downside Seeking Alpha - Mar 13, 2017 The company has also been rumored to be making a bid for Incyte . I own the stock in my Portfolio of 12 and the stock hasn't performed to my expectations.Gilead Sciences: Is an Incyte Deal 'Reasonable'? - Barron's What a Combined Gilead and Incyte Would Look Like - 24/7 Wall St."
p10
a.